Cannabis Cuts Opioid Prescriptions By 53%, Utah Study Suggests
Recent research in Utah highlights cannabis as a potential game-changer in pain management. A study by Management Science Associates (MSA) found a 53% drop in opioid prescriptions among chronic pain patients who used cannabis between 2021 and 2024.
The study, presented at a Medical Cannabis Policy Advisory Board meeting, examined data from 186 patients. It revealed that 84.4% of participants reduced opioid use after starting cannabis treatment, with the greatest reduction seen in neuropathic pain (73.5%).
Insights From Utah And Minnesota Studies
Notably, vapes (67.6%), gummies (53.3%) and tinctures (19%) were the preferred products. However, chronic headache and orofacial pain patients experienced increased opioid use, underscoring the need for targeted treatments.
- Get Benzinga’s exclusive analysis and the top news about the cannabis industry and markets …